D&D Pharmatech Announces The Lancet Gastroenterology & Hepatology Publication of Phase 2 Data Demonstrating Rapid, Weight-Independent Activity of Zabopegdutide (DD01) in MASLD/MASH
D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company developing breakthrough treatments for liver and metabolic diseases, today announced the publication of 12-week results from its Phase 2 DD01-DN-2 study evaluating zabopegdutide (DD01) in patients with MASLD/MASH in the Lancet Gastroenterology & Hepatology.
The publication follows D&D’s recent announcement of positive 48-week Phase 2 biopsy results, in which zabopegdutide achieved statistically significant improvements in both MASH resolution and fibrosis improvement in patients with biopsy-confirmed MASH and fibrosis stage F1-F3 (businesswire). The newly published analysis demonstrates that the robust histological benefits observed after 48 weeks were preceded by rapid, clinically meaningful improvements in liver fat, liver stiffness, and fibrosis biomarkers as early as 12 weeks, supporting the potential of these non-invasive markers to predict long-term histological benefit.
“Our recently announced 48-week biopsy results established that zabopegdutide produces clinically meaningful histological improvements in patients with MASH,” said Seulki Lee, Ph.D., President and CEO of D&D Pharmatech. “The publication in the Lancet Gastroenterology & Hepatology demonstrates that these outcomes were foreshadowed by rapid and substantial improvements in liver health within the first 12 weeks of treatment. Importantly, many of these benefits occurred before meaningful weight loss, suggesting that zabopegdutide provides direct therapeutic effects on the liver beyond weight reduction. Together, these findings highlight the differentiated profile of zabopegdutide and support its potential to become a best-in-class therapy for MASH.”
